These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14639671)

  • 21. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
    Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
    Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
    Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L; Morin N; Ouattara B; Gasparini F; Bilbe G; Johns D; Vranesic I; Sahasranaman S; Gomez-Mancilla B; Di Paolo T
    Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.
    Hill MP; Brotchie JM; Crossman AR; Bezard E; Michel A; Grimée R; Klitgaard H
    Clin Neuropharmacol; 2004; 27(4):171-7. PubMed ID: 15319703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
    Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N; Grégoire L; Bédard PJ; Di Paolo T
    Neurobiol Aging; 2006 Nov; 27(11):1684-93. PubMed ID: 16253392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.